ECSP056164A - Compuestos utiles para el tratamiento de enfermedades - Google Patents

Compuestos utiles para el tratamiento de enfermedades

Info

Publication number
ECSP056164A
ECSP056164A EC2005006164A ECSP056164A ECSP056164A EC SP056164 A ECSP056164 A EC SP056164A EC 2005006164 A EC2005006164 A EC 2005006164A EC SP056164 A ECSP056164 A EC SP056164A EC SP056164 A ECSP056164 A EC SP056164A
Authority
EC
Ecuador
Prior art keywords
diseases
treatment
useful compounds
disorders
derivatives
Prior art date
Application number
EC2005006164A
Other languages
English (en)
Inventor
Mark Edward Bunnage
Paul Alan Glossop
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP056164A publication Critical patent/ECSP056164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

La invención se refiere a compuestos de fórmula (1) y a procesos para la preparación de tales derivados, a intermedios usados en su preparación, a composiciones que los contienen y a los usos de tales derivados. Los compuestos de acuerdo con la presente invención son útiles en numerosas enfermedades, trastornos y afecciones, en particular enfermedades, trastornos y afecciones inflamatorias, alérgicas y respiratorias.
EC2005006164A 2003-05-15 2005-11-15 Compuestos utiles para el tratamiento de enfermedades ECSP056164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010944A EP1477167A1 (en) 2003-05-15 2003-05-15 [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
GBGB0329874.2A GB0329874D0 (en) 2003-05-15 2003-12-23 Compounds useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
ECSP056164A true ECSP056164A (es) 2006-04-19

Family

ID=33454327

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006164A ECSP056164A (es) 2003-05-15 2005-11-15 Compuestos utiles para el tratamiento de enfermedades

Country Status (29)

Country Link
EP (2) EP1477167A1 (es)
JP (1) JP3966897B2 (es)
KR (1) KR100749990B1 (es)
CN (1) CN1791407A (es)
AP (1) AP2005003443A0 (es)
AR (1) AR044335A1 (es)
AT (1) ATE413879T1 (es)
AU (1) AU2004237952A1 (es)
BR (1) BRPI0410391A (es)
CA (1) CA2525006A1 (es)
CL (1) CL2004000963A1 (es)
CO (1) CO5700776A2 (es)
DE (1) DE602004017710D1 (es)
DK (1) DK1624868T3 (es)
EA (1) EA200501615A1 (es)
EC (1) ECSP056164A (es)
ES (1) ES2314395T3 (es)
GB (1) GB0329874D0 (es)
IS (1) IS8080A (es)
MA (1) MA27840A1 (es)
MX (1) MXPA05012329A (es)
NL (1) NL1026203C2 (es)
NO (1) NO20055854L (es)
OA (1) OA13165A (es)
PA (1) PA8603001A1 (es)
PE (1) PE20060095A1 (es)
TW (1) TW200505865A (es)
UY (1) UY28317A1 (es)
WO (1) WO2004100950A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84048C2 (ru) * 2004-01-22 2008-09-10 Пфайзер Инк. Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
JP4036343B2 (ja) * 2004-01-22 2008-01-23 ファイザー・インク 疾患の治療のためのスルフォンアミド誘導体
AU2005223488A1 (en) * 2004-03-17 2005-09-29 Pfizer Inc. Phenylethanolamine derivatives as Beta-2 agonists
WO2005092887A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20080036632A (ko) 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5629200A (en) * 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
MX9708621A (es) * 1995-05-10 1998-02-28 Pfizer AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS.
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist

Also Published As

Publication number Publication date
EP1624868B9 (en) 2009-08-12
IS8080A (is) 2005-10-20
NL1026203C2 (nl) 2005-07-26
AP2005003443A0 (en) 2005-12-31
ES2314395T3 (es) 2009-03-16
CN1791407A (zh) 2006-06-21
NO20055854L (no) 2006-02-10
KR100749990B1 (ko) 2007-08-16
AR044335A1 (es) 2005-09-07
DE602004017710D1 (de) 2008-12-24
CO5700776A2 (es) 2006-11-30
KR20060017607A (ko) 2006-02-24
UY28317A1 (es) 2004-12-31
BRPI0410391A (pt) 2006-07-18
ATE413879T1 (de) 2008-11-15
EP1624868B1 (en) 2008-11-12
OA13165A (en) 2006-12-13
DK1624868T3 (da) 2009-02-23
AU2004237952A1 (en) 2004-11-25
CL2004000963A1 (es) 2005-03-18
EP1477167A1 (en) 2004-11-17
MA27840A1 (fr) 2006-04-03
NL1026203A1 (nl) 2004-11-16
JP2007503458A (ja) 2007-02-22
GB0329874D0 (en) 2004-01-28
PE20060095A1 (es) 2006-02-18
EP1624868A1 (en) 2006-02-15
TW200505865A (en) 2005-02-16
MXPA05012329A (es) 2006-01-30
CA2525006A1 (en) 2004-11-25
WO2004100950A1 (en) 2004-11-25
JP3966897B2 (ja) 2007-08-29
EA200501615A1 (ru) 2006-06-30
PA8603001A1 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
ECSP056164A (es) Compuestos utiles para el tratamiento de enfermedades
UY28724A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY28343A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
UY28721A1 (es) Derivados de sulfonamida para eltratamiento de enfermedades
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
UY28339A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
ECSP11010754A (es) Derivados de triazol útiles para el tratamiento de enfermedades
CR10235A (es) Derivados de amina
CR10700A (es) Derivados de sulfonamida
CR8636A (es) Compuestos utiles para el tratamiento de enfermedades
UY28819A1 (es) Derivados de formamida para el tratamiento de enfermedades
DOP2004000902A (es) Compuestos utiles para el tratamiento de enfermedades
UY28816A1 (es) Compuestos para el tratamiento de enfermedades
ECSP066854A (es) Compuestos utiles para el tratamiento de enfermedades
DOP2005000037A (es) Compuestos utiles para el tratamiento de enfermedades
DOP2004000921A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
CR9838A (es) Derivados de sulfonamida para el tratamiento de enfermedades
CR8513A (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2005000043A (es) Compuestos para el tratamiento de enfermedades
DOP2005000041A (es) Compuestos para el tratamientos de enfermandades
CU23532B7 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CU23537B7 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CU23661B7 (es) Derivados de formamida para el tratamiento de enfermedades
CR8514A (es) Derivados de sulfonamida para el tratamiento de enfermedades